|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:capacity
|
1 m L
|
|
gptkbp:clinical_trial
|
Phase 3
HELP Study
KALAHARI Study
HELP2 Study
|
|
gptkbp:clinical_use
|
chronic treatment
|
|
gptkbp:contraindication
|
hypersensitivity to lanadelumab
|
|
gptkbp:developed_by
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:drug_interactions
|
none significant
|
|
gptkbp:duration
|
long-term therapy
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:healthcare
|
gptkb:pharmaceuticals
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lanadelumab
|
|
gptkbp:indication
|
prevention of angioedema attacks
|
|
gptkbp:ingredients
|
gptkb:lanadelumab
|
|
gptkbp:invention
|
2028
|
|
gptkbp:is_monitored_by
|
angioedema attack frequency
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibition of plasma kallikrein
|
|
gptkbp:notable_work
|
effective in reducing attacks
|
|
gptkbp:patient_education
|
necessary for self-administration
|
|
gptkbp:patient_population
|
adults and adolescents
|
|
gptkbp:pharmacokinetics
|
long half-life
dose-dependent efficacy
|
|
gptkbp:pharmacovigilance
|
ongoing monitoring
|
|
gptkbp:price
|
high
|
|
gptkbp:production_status
|
marketed product
|
|
gptkbp:provides_guidance_on
|
recommended for prophylaxis
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:research_areas
|
gptkb:hereditary_angioedema
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
every 2 to 4 weeks
|
|
gptkbp:side_effect
|
headache
injection site reactions
rare serious allergic reactions
nasopharyngitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:structure
|
Ig G1 monoclonal antibody
|
|
gptkbp:targets
|
plasma kallikrein
|
|
gptkbp:trade
|
gptkb:Takhzyro
|
|
gptkbp:treatment
|
improved quality of life
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:used_for
|
treatment of hereditary angioedema
|
|
gptkbp:website
|
abdomen or thigh
|
|
gptkbp:bfsParent
|
gptkb:Takhzyro
|
|
gptkbp:bfsLayer
|
6
|